Icahn Asks Amylin to Allow Discussions With Eastbourne
NEW YORK, April 23, 2009 /PRNewswire/ -- Carl Icahn announced today that he had sent the following letter to James Wilson, Lead Independent Director of Amylin Pharmaceuticals, Inc. .
April 23, 2009 Mr. James Wilson Lead Independent Director Amylin Pharmaceuticals, Inc. 9360 Towne Centre Drive San Diego, CA 92121 Dear Jim: If you are really serious about settling what you consider a debilitating proxy contest, I believe it is mandatory for you to take the necessary action to allow Eastbourne and myself to talk without the threat of your poison pill and Section 203 preventing these discussions. It is almost absurd that I and Eastbourne, separately, have had to ask you a number of times during last week and the week before to get permission to have these talks. As I have said, even in a dictatorship parties that disagree with the ruling regime are allowed to talk to each other. But not at Amylin. I sincerely believe that as a result of these discussions and subsequent discussions among the three of us, there will be enough common ground to resolve the matter. What exactly are you afraid of? The alternative is for the Company and its stockholders to continue to be distracted because of the inexplicable intransigence of the current Board which continues to evidence itself in so many ways, e.g. the poison pill, the poison puts, and the failure to heed the views of your co-founder, Howard E. Greene, Jr., regarding Joseph Cook's board seat. I look forward to your prompt response. Sincerely, Carl Icahn
SECURITY HOLDERS ARE ADVISED TO READ THE PROXY STATEMENT AND OTHER DOCUMENTS RELATED TO THE SOLICITATION OF PROXIES BY CARL C. ICAHN, DR. ALEXANDER J. DENNER, DR. THOMAS F. DEUEL, MR. JULES HAIMOVITZ, DR. PETER LIEBERT, DR. DAVID SIDRANSKY, MR. MAYU SRIS, MR. JEFFREY MECKLER, DR. ERIC ENDE, ICAHN Partners LP, Icahn Partners Master Fund LP, Icahn Partners Master Fund II LP, Icahn Partners Master Fund III LP, Icahn Enterprises G.P. Inc., Icahn Enterprises Holdings L.P., IPH GP LLC, Icahn Capital L.P., Icahn Onshore LP, Icahn Offshore LP, Beckton Corp., AND CERTAIN OF THEIR RESPECTIVE AFFILIATES FROM THE STOCKHOLDERS OF AMYLIN PHARMACEUTICALS, INC, FOR USE AT ITS ANNUAL MEETING WHEN THEY BECOME AVAILABLE, BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION, INCLUDING INFORMATION RELATING TO THE PARTICIPANTS IN ANY SUCH PROXY SOLICITATION. WHEN COMPLETED, A DEFINITIVE PROXY STATEMENT AND A FORM OF PROXY WILL BE AVAILABLE TO STOCKHOLDERS OF AMYLIN PHARMACEUTICALS, INC. FROM THE PARTICIPANTS AT NO CHARGE AND WILL ALSO BE AVAILABLE AT NO CHARGE AT THE SECURITIES AND EXCHANGE COMMISSION'S WEBSITE AT .
INFORMATION RELATING TO THE PARTICIPANTS IN THIS PROXY SOLICITATION IS CONTAINED IN SCHEDULE 14A FILED BY THE PARTICIPANTS WITH THE SECURITIES AND EXCHANGE COMMISSION, WHICH DOCUMENTS ARE AVAILABLE AT NO CHARGE AT THE SECURITIES AND EXCHANGE COMMISSION'S WEBSITE AT .
CONTACT: Susan Gordon, +1-212-702-4309
Ticker Symbol: (NASDAQ-NMS:AMLN)
Terms and conditions of use apply
Copyright © 2009 PR Newswire Association LLC. All rights reserved.
A United Business Media Company
Posted: April 2009